Purpose Chronic graft-versus-host disease (cGVHD) is a significant cause of mortality and morbidity after allogeneic hematopoietic cell transplant and is associated with a wide range of distressing symptoms. A pediatric measure of cGVHDrelated symptoms is needed to advance clinical research. Our aim was to elicit descriptions of the cGVHD symptom experience directly from children and to compare the specific language used by children to describe their symptoms and the comprehension of symptom concepts across the developmental spectrum. Methods We used qualitative methods to identify the phrases, terms, and constructs that children (ages 5-8 [n =8], 9-12 [n =8], and 13-17 [n =8]) with cGVHD employ when describing their symptoms. The symptom experience of each participant was determined through individual interviews with each participant and parent (5-7 year olds were interviewed together with a parent). Medical practitioners with experience in evaluating cGVHD performed clinical assessments of each participant. Results Pediatric transplant survivors and their parents identified a wide range of bothersome cGVHD symptoms, and common concepts and terminologies to describe these experiences emerged. Overall concordance between patient and parent reports was moderate (70-75 %). No consistent pattern of child under-or over-reporting in comparison to the parent report was observed. Conclusion These study results identify concepts and vocabulary to inform item generation for a new pediatric self-report measure of cGVHD symptoms for use in clinical research. The findings also confirm the prevalence and nature of symptom distress in pediatric patients with cGVHD and support implementation of systematic approaches to symptom assessment and intervention in routine clinical practice.
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Introduction
Chronic graft-versus-host disease (cGVHD) is a condition of immune dysregulation that usually occurs 100 days and beyond following allogeneic hematopoietic stem cell transplantation. This late complication of transplantation is the leading cause of morbidity and mortality in children undergoing transplantation and carries a 59 % survival rate at 5 years after cGVHD diagnosis [1] . Chronic GVHD develops in 20-60 % of transplant recipients [2] [3] [4] , and its symptoms are heterogeneous, including skin changes (lichenoid and sclerotic changes), joint contractures, severe muscle cramping, sicca syndrome, oral ulcers, esophageal dysmotility, nausea, poor appetite, weight loss, and polyserositis [5, 6] . Chronic GVHD therapy in children is often protracted, and the rate of discontinuation of immunosuppression is only 37 % at 5 years after its diagnosis [1] . Better tools to capture the burden of cGVHD at diagnosis and follow-up are essential to be able to adequately optimize the treatment.
Traditionally, cGVHD has been classified as "limited" or "extensive," though these distinctions are not particularly useful in clinical practice. The waxing and waning nature of cGVHD and the diversity of its clinical manifestations make management and assessment of this disease very complicated. In 2005, NIH cGVHD individual organ and global severity scoring was proposed to standardize clinician evaluation and staging of cGVHD in an effort to establish consistent response criteria for patients enrolled on clinical trials [7, 8] . Since then, prospective natural history cGVHD studies have shown that the overall severity score as well as individual scores in specific organs such as skin are predictive of survival [9, 10] .
Mortality and time to discontinuation of immunosuppressive therapy are often used as endpoints in cGVHD trials. Although objective and important measures of cGVHD, these are not always practical or informative measures of disease burden. Surrogate endpoints are needed and may prove to be more informative and practical in cGVHD clinical trials and in clinical care. One important measure of disease burden is health-related quality of life (HRQOL) [11] . To date, there are no pediatric scales to assess symptoms of cGVHD. Several pediatric measures are being used to evaluate the HRQOL of children living with GVHD such as the PedsQL cancer module [12] for children with cancer, Minneapolis-Manchester Quality of Life (MMQL) [13, 14] , and Child Health Ratings Inventories (CHRIs) [15, 16] for survivors of pediatric stem cell transplant. General HRQOL instruments capture domains such as emotional well being (e.g., anxiety and depression), whereas disease-specific instruments capture specific symptoms (e.g., itching, diarrhea, and shortness of breath) directly related to the disease. Because none of these instruments is specific for cGVHD, each has potential content validity limitations in assessing the full spectrum of symptoms experienced by children with cGVHD.
The Lee cGVHD Symptom Scale is a validated measure of the degree to which adults are bothered by each of 30 cGVHD specific symptoms [17] . The Lee Scale correlates with therapeutic response in patients with newly diagnosed cGVHD [18] ; however, this measure has not been validated for use in children or their parent proxies. Importantly, item generation for a pediatric symptom scale requires that the symptom concepts and phrasing be identified based on concept elicitations interviews with individuals from the target patient population [19] . No prior research has systematically explored child and parent perspectives of the symptoms associated with cGVHD. The objectives of this study were to inform the development of a pediatric cGVHD symptom scale by describing the physical and emotional symptoms of cGVHD from the child and parent perspective and exploring the language and symptom concepts used by children across the developmental spectrum to describe the cGVHD symptoms they find to be bothersome.
Materials and methods
To ensure the developmental appropriateness of pediatric patient-reported outcome (PRO) measures, both the US Food and Drug Administration [20] and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [19] recommend that qualitative interviews with the targeted patient population be conducted for concept elicitation and to inform item generation and support content validity of new PRO instruments. Because children may use different words than adults when describing their experiences, it is particularly important that the child's perspective be incorporated when establishing content validity [20] . Thus, a qualitative approach was used to identify the constructs and specific language children with cGVHD use to describe their symptom experience.
Individual interviews were conducted separately with each pediatric cGVHD patient over the age of 8 and with their parent; 5-7 year old participants were interviewed together with a parent. The design and implementation of the study followed the published principles and best practices for successfully conducting cognitive interviews with children [19] [20] [21] Data were extracted from the medical record including underlying disease, type of transplant, stem cell source, donor type, HLA mismatch, time since transplant, prior cGVHD treatment regimens, and current cGVHD treatment regimen. The NIH cGVHD Consensus criteria forms (cGVHD organ score and response criteria form) were completed by a practitioner (physician or advanced practice nurse) with experience in performing comprehensive cGVHD clinical evaluations.
Interview guide
Five experts (three physicians and two nurses) with experience in pediatric hematopoietic stem cell transplantation (HSCT) and cGVHD developed an interview guide that was used during each of the audio-recorded interviews (Fig. 1a, b) . The guides were designed to trigger responses that would optimize the probability that all the symptoms the child was experiencing would be reported during the interview. As the symptoms associated with cGVHD relate directly to the disease pathophysiology and the side effects of immunosuppression, it was assumed that the symptoms experienced by children would be comparable to those of adults (e.g., dry eyes and skin itching), although the associated symptom distress, interference, illness concepts, and language used by children would be different and would vary across the developmental spectrum. Thus, the cGVHD symptoms identified by adults in prior research provided a starting point to develop the openended questions [17] . Participants were also encouraged to identify concerns in specific content areas. For example, "What bothers you (your child) or ever bothered you (your child) most about your (your child's) skin?" and "What are other concerns you have had with your (your child's) skin?"
As quantitative approaches to sample size estimation are not applicable in a qualitative study, researchers considered the variability of the target population characteristics when determining sample size [22] . Interviews continued until saturation, defined as the point at which no new information or themes emerged, was documented [19, 23] . Previous research has found that after 12 interviews, between 88 and 92 % of analysis codes (themes) can be identified [22, 24] . Investigators designed this study with a sample size of 24 (eight participant pairs in each age group) realizing that a second cohort might need to be recruited to achieve saturation.
Participants
Children (ages 5 to 17 years old) with a current clinical diagnosis of cGVHD needing systemic treatment and who were without evidence of primary disease relapse were eligible, together with a parent, to participate in this study. Each member of the dyad provided informed consent or, if applicable, child assent. Study subjects were consecutively recruited by principal investigators at each site, and participants were enrolled after informed consent was obtained.
To represent a broad spectrum of developmental perspectives, the dyads were grouped into three age cohorts (5-8 years, 9-12 years, and 13-17 years), based on the age of the child respondent [20] . Evidence suggests that self-report measures may have limited validity and reliability among respondents younger than age 5 and that assessment of health status in children less than 5 years of age must rely on clinical measures and observational reports of parents or other observers [20] . Accordingly, in our study, 5 to 8 year olds (n =8) were interviewed together with their parent since these younger children were anticipated to have a more limited vocabulary, and a less developed understanding of health and illness concepts, and thus the value of the information they provided would be enhanced by interviewing parent and child together. A total of 40 interviews were conducted (n =16 children alone, 16 parents alone, and 8 parents and children together). The interviews ranged from 20 to 90 min. If the child or parent's primary language was Spanish, a professional translator was used for the entire interview (n =2).
Conference calls with participating sites took place throughout data collection to ensure data completeness, promote consistency of procedures across study sites, and address study-wide interviewer issues and ongoing recruitment. NIH diagnosis and staging [7] and other demographic and clinical variables were assembled using standardized case report forms, and the audio-recorded interviews together with the case report forms were securely shipped to the study sponsoring PI (DJ) where they were monitored for quality assurance and reviewed for consistency. The audio-recorded interviews were transcribed by a professional transcription service. For the Spanish interviewees, transcripts were first prepared in Spanish and then translated.
Data analysis
The first step of the analysis involved reading through the interview transcripts and developing a coding structure. Using an inductive approach, concept codes were labeled and clearly defined to guide the analysis. To reduce bias, three independent health professionals with experience in qualitative data analysis independently performed the coding of all transcripts using the coding dictionary. Intra-class correlation coefficients (ICC) were calculated to assess interrater reliability between the three raters in their coding of the presence of symptoms for both parent and child reports. All ICC were significant, most at the p <0.001 level. The median ICC was 0.91 (range 0.76-1.0).
In order to describe the prevalence of each of the cGVHD symptoms, congruence was sought between coders for each symptom reported (for parent and child report, separately). When discrepancies between coders occurred, one of the investigators was consulted (LW) to reconcile differences (LW). Once congruence was obtained for all symptoms, a detailed description of each endorsed symptom and symptom location was developed for each participant age grouping.
Once convergence among coders was achieved for all symptoms, a detailed description of each endorsed symptom was summarized for each participant age grouping. Concept saturation, that is the point at which no new changes to the coding dictionary emerged, was achieved after the analysis of two thirds of the interviews. Table 1 details participant characteristics. Participants ranged in age from 5 to 17 years (mean=11). Eighty-three percent were transplanted for a malignancy, and 71 % underwent a full-intensity preparative regimen. Over half (51 %) had been diagnosed with acute GVHD grade II-IV previously. All patients had received multiple therapies for chronic GVHD and the majority were on systematic corticosteroids at the time of interview (92 %). Table 2 details organs involved (NIH score ≥1) by age group and for the whole cohort, and Fig. 2 details the mean (with SD) NIH score for each organ. Symptoms by age groups Table 3 details the patient and parent symptom reports. Differences between age groups are described below; however, given the small within-age sample size, there was insufficient power to detect statistically significant differences. Areas of worry were consistent throughout the child interviews regardless of age. Of those who reported "worrying a lot," 57 % worried about their appearance, 29 % about not getting better, and 29 % about social concerns, including school attendance. Table 4 details the terms and phases that study participants used to describe their symptoms.
Results

Participant characteristics
Ages 5-8 Children ages 5-7 years were interviewed together with a parent. Within this age group, the most common reported skin manifestations were rash (88 %), discoloration (83 %), and thick skin (71 %). Seventy-five percent of the parents interviewed reported that their child's eyes "bothered them" (predominately due to dryness [38 %]), 71 % reported that their child was bothered by diarrhea, and 75 % indicated their child was experiencing poor appetite. Muscle and joint problems were also frequent (83 %), with the most common concern being muscle weakness (80 %).
Ages 9-12 There were high rates of symptom reports in each of the eight domains explored in this age group. Eyes were commonly reported as symptomatic by patients and parents (63 and 88 %, respectively), with 75 % of children specifying eye dryness and half of children reporting eye pain and difficulty seeing. Skin discoloration was the most common skin symptom reported (children 50 %, parents 88 %) and many children reported mouth problems (63 %) and avoiding certain foods (children 75 %, parents 88 %). Many children reported worrying a lot (63 %); however, comparatively fewer participants indicated that they lacked friends (13 %).
The symptoms with the highest concordance (100 %) between parent and child were skin sores, nail peeling, problems eating, fatigue, overall shortness of breath, and constipation. Symptoms with the least concordance were eye dryness (43 %), bothersome muscles and/or joints (38 %), and shortness of breath while running (40 %).
Ages 13-17
As with the 9-12 year olds, skin discoloration was a commonly reported symptom (children 67 %, parents 88 %). Eye problems were similarly reported as bothersome by patients in this age group, but "dry eyes" were less problematic. Also commonly endorsed were nail peeling, mouth problems, bothersome muscles and joints, weak muscles, and shortness of breath when running. Seventy-five percent of children endorsed feelings of sadness and worry. None endorsed having a lack of friends.
The symptoms with the highest concordance (100 %) between parent and child were poor appetite, shortness of breath within a few steps, shortness of breath when running, and concerns about a lack of friends. Symptoms with the least amount of concordance were fatiguability (children 33 %, parent 100 %), muscle pain (children 29 %, parent 63 %), and skin rashes (children 75 %, parent 38 %).
Discussion
Assessment of symptoms associated with cGVHD in children can provide useful information about current health status, distinguish children with differing levels of cGVHD severity and resultant morbidity, identify individuals who warrant clinical intervention for symptom distress, and improve our understanding of the impact of cGVHD on functioning and lifestyle from the child/adolescent's perspective. This study explored the experience of cGVHD symptom distress among children, with an emphasis on comparing the specific language used by children to describe their cGVHD symptoms and their comprehension of symptom concepts across the developmental spectrum. The study also identified more comprehensive and specific descriptions of cGVHD symptoms than would be obtained using generic health-related quality of life or symptom scales. Specifically, we found that pediatric patients over 9 years of age can identify and report organspecific symptoms. Common language emerged to reflect these symptoms (for example, "skin bumpy," "mouth burning," "white bumps that you can't pop in the mouth," "tickle in the throat"). Overall concordance between patient and parent report for the 9-12 and 13-17 age groups was moderate and perhaps surprisingly, the distribution of high or low concordance was approximately equal across more subjective symptoms (such as fatigue, or muscle pain) and what would be considered more objective symptoms, like skin rash. No consistent pattern of child under-or over-reporting in comparison to the parent report was observed.
When comparing patient symptom reports to the clinicianrated NIH organ scores, which are based on a combination of subjective and objective criteria, we observed higher symptom reporting by patients and parents compared with clinician rating of the severity of cGVHD organ involvement in almost all categories. For example, only 46 % of patients had an NIH eye score ≥1, but "eye bother" was endorsed by 63 % of patients in the 9-12 and 13-17 age groups and by 75 % of the parent-child dyads in the 5-8-year-old age group. This observation is consistent with the findings of other investigators, and the reasons are likely multifactorial. Children and their parent were reporting the symptoms that caused the child bother or distress, whereas clinicians were scoring cGVHD severity using a combination of disease signs and symptoms. Other factors which may have contributed to observing only partial concordance between clinician cGVHD severity rating and patient-reported symptoms include medication side effects, the long-term sequelae of prior treatment, and limitations in performing clinical assessments for cGVHD severity in younger children (e.g., inability to perform Schirmer's test, pulmonary functions tests, etc.). A number of studies in adults have shown that patient and clinician ratings are only partially concordant, and our results provide additional evidence to suggest that self-report may complement rather than duplicate clinician-reported outcome measures in cGVHD [25, 26] .
While the inclusion of pediatric patients across the age spectrum and the multi-institutional design were strengths of the study, a few limitations should be noted. As this was the initial study to obtain both parent and patient data in an exploratory fashion, our sample size was relatively small. It was reassuring however, that saturation was reached in each of the age groups studied, suggesting that the sample size was adequate for the study. One factor that can limit accuracy in qualitative interviews and recall studies with youth is the recency effect. That is, typically, recent symptoms will be recalled, especially those that might have occurred in the past 24 h. Prompts were needed for younger children to report using a recall period that extended beyond the past day. Inclusion of the parent in the interview of 5-7 year olds was also designed to mitigate possible recency effects. Lastly, some of the signs and symptoms that were reported by patients and their parents are experienced in HSCT recipients without Skin discoloration  83  88  50  88  67  83  59   Skin rash  88  29  38  38  75  52  57  Nail peeling  43  43  38  75  71  54  55  Thick skin  71  33  0  43  0  49  0  Skin tightness  17  38  13  17  0 29  0  14  13  39  7  Difficulty swallowing  29  25  0  38  13  31  7  Constipation  0  17  13  0  25  6  19  Muscles and joints Muscles/joints bothersome 83  88  25  88  75  86  50  Weak muscles  80  100  50  71  86  84  68  Muscle cramping  33  86  75  38  57  52  66  Tight joints  67  83  50  71  57  52  54  Muscle pain  50  57  38  63  29  57  24  Difficulty moving  50  71  14  40  33  54  24  Unable to run  38  43  13  57  50  46  32  Lungs  Short of breath: running  43  67  86  100  100  70  93  Short of breath: walking  up stairs   60  86  63  50  67  65 "I noticed that my hand or something might get stuck if I write or something and they all of a sudden might get stuck in one place cGVHD, or may represent adverse effects of cGVHD therapies (e.g., muscle weakness, stretch marks and weight gain caused by corticosteroids). Future studies are needed to explore the prevalence and severity of symptoms comparing HSCT recipients with and those without cGVHD.
Next steps
Our findings can be applied towards the development of a pediatric GVHD symptom scale. There exists no generic or cancer-specific pediatric symptom measure that captures the full range of symptoms described in the qualitative interviews. As expected, the global domains within which cGVHD symptoms can be grouped (e.g., lung, skin, etc.) did not differ from the Lee Scale; however, across the three age groups studied, children used different vocabulary across to describe many of their symptoms. A pediatric scale must use developmentally appropriate symptom constructs and phrasing in order to be well understood by respondents of varying ages. There remains a fundamental role for parent proxy report in pediatric clinical trials and health services research, particularly when children are unable to provide self-report. Even when children are able to self-report, parent proxy report should be considered as a secondary outcome measure given parents' expanding role in clinical decision making and home treatment regimens for pediatric chronic health conditions [27] . Ideally, parent and child HRQOL instruments should measure the same constructs with parallel items in order to make comparisons between self and proxy report more meaningful [28, 29] .
The study group is currently using the data derived from the qualitative interviews to generate a pool of items that will ultimately comprise a pediatric cGVHD symptom scale. All items will inquire about symptoms that have bothered the child in the last week, the severity of the symptom, and whether the symptom interfered with the child's usual daily activities. Two forms will be developed: a child self-report and also a corresponding parent report of the child's symptoms. FDA guidelines recommend that instrument development for children and adolescents be conducted within fairly narrow age groupings [30] . After the items have had preliminary pilot testing, cognitive interviewing within the age groupings specified for this study will be conducted to refine the symptom items and the response choices to ensure their comprehension by children and adolescents across the developmental spectrum. Following this, a quantitative psychometric validation study will be conducted.
PRO measures are increasingly used in studies evaluating new therapies in order to provide a more comprehensive picture of treatment effects. Our research efforts represent an important and timely step in the development of an ageappropriate outcome measure for cGVHD symptoms, toward 
